Strategies to overcome drug resistance using SHP2 inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2), encoded by PTPN11, is a critical regulator of cellular signaling pathways.
• SHP2's role in oncogenesis and immune modulation within the tumor microenvironment makes it a significant anti-cancer drug target.
• Dysregulation of SHP2 activity is implicated in various cancers.

Purpose of the Study:

• To review the structure, function, and small molecule inhibitors of SHP2.
• To highlight the therapeutic potential of SHP2 inhibitors in overcoming drug resistance.
• To provide insights for the future clinical development of SHP2-targeted therapies.

Main Methods:

• Literature review of SHP2 structure and function.
• Analysis of existing SHP2 allosteric inhibitors in clinical studies.
• Examination of recent research on SHP2 inhibitors for overcoming drug resistance.

Main Results:

• Five SHP2 allosteric inhibitors have entered clinical trials for cancer treatment.
• SHP2 inhibitors demonstrate potential in overcoming resistance to kinase inhibitors and PD-1 blockade.
• SHP2 regulates key signaling pathways including RAS-RAF-ERK, PI3K-AKT, and JAK-STAT.

Conclusions:

• SHP2 is a validated anti-cancer target with significant therapeutic potential.
• Targeting SHP2 offers a promising strategy to enhance the efficacy of existing cancer treatments.
• Further clinical development of SHP2 inhibitors is warranted to improve patient outcomes.